Alnylam To Report New Clinical Results With Fitusiran At The World Federation of Hemophilia 2016 World Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that Alnylam and collaborators will present interim results from the ongoing Phase 1 clinical trial with fitusiran, an investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia A and B and rare bleeding disorders (RBD) at the World Federation of Hemophilia (WFH) 2016 World Congress being held July 24 – 28, 2016 in Orlando, Florida.

Back to news